The fast-moving world of precision oncology demands an operational engine that is just as sophisticated as the science behind it. In the May 2026 edition of the 1Cell.Ai newsletter, CEO Mohan Uttarwar introduces a purposeful organizational transformation. Led by industry veteran Dr. Nilesh Shah, the company has tightened laboratory turnaround times and introduced key clinician-centric initiatives—including a no-cost, on-demand Molecular Helpline to discuss complex reports and a partnership-first clinical team.
A major highlight of this issue is the official launch of OncoIndx 360 Endometrium. Endometrial cancer management has long faced a classification problem, with critical molecular subtypes often sequenced one at a time or missed entirely. This comprehensive new panel collapses the entire diagnostic workflow into a single tissue sample, simultaneously evaluating POLE, MMR/MSI, TP53, NSMP, HER2, and pharmacogenomics to deliver a complete molecular portrait from Day 1.
This edition also features a compelling real-world case study where OncoIndx 360 completely altered the treatment path for a 54-year-old woman initially classified with low-risk endometrial cancer. The panel uncovered a critical CTNNB1 mutation—invisible to conventional workup—reclassifying her risk to intermediate and enabling targeted, timely intervention. Check out the full newsletter to read more about this case and catch up on global oncology news, including the rising prominence of autonomous AI frameworks in cancer discovery